MARKET NEWS

Increased Security for Connected Medical Devices to Drive Cybersecurity Market to $143 Billion
Sienna Biopharmaceuticals Files 510(k) Submission With FDA
Stevanato Group Signs License Exclusive Agreement With Haselmeier
MilliporeSigma Becomes the First to Use Acoustic Technology for Cell Therapy Manufacturing
Akcea & Pfizer Announce $250-Million Licensing Agreement for Investigative Therapy
Bormioli Pharma Completes Acquisition of Remy & Geiser

  FEATURED EDITORIAL

  COMPANY PROFILE

Ascendia Pharmaceuticals is a speciality contract development and manufacturing (CDMO) company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates.  We specialize in creating formulation solutions for poorly-water soluble molecules and other challenging pharmaceutical development projects.  Using our suite of formulation capabilities and nano-particle technologies, we can assess the feasibility of a broad array of formulation options in order to improve a drug’s bioavailability.  Ascendia formulates products for injection (IV, SC, or IM), transdermal, ophthalmic or nasal delivery, and both immediate-release and controlled-release products for oral administration. We execute rapid, comprehensive, and cost-effective programs for our clients. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Pfenex Receives US FDA Approval for PF708 to Treat Osteoporosis

Pfenex Receives US FDA Approval for PF708 to Treat Osteoporosis

Pfenex Inc. recently announced the US FDA has approved the new drug application (NDA) for PF708 submitted under the 505(b)(2) regulatory pathway, with…

Streamlining Drug Development Processes Through the Accenture INTIENT Clinical Platform

Streamlining Drug Development Processes Through the Accenture INTIENT Clinical Platform

To facilitate the demand for this new world order, we’ve unveiled the Accenture INTIENT Clinical platform. It helps companies run faster clinical trials with better transparency and….

Gerresheimer Opens US Glass Innovation & Technology Center

Gerresheimer Opens US Glass Innovation & Technology Center

Gerresheimer is driving innovation in pharmaceutical glass, primary packaging glass products, technologies, and digitized processes. In the future, highly qualified engineers at the recently opened Gx Glass Innovation and Technology Center will develop….

FORMULATION FORUM - Rational Design & Development of Long-Acting Injectable Dosage Forms

Due to the advantages of parenteral sustained-release drug delivery (also known as long-acting injectables, LAIs) different types of sustained-release injectable delivery systems have been….

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 23 – Capsules
October 30 – Analytical Testing